ArticlePharmacoEconomics - open2025

Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients.

Silvia Fenix-Caballero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.